Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.
Q2 2025 Highlights
Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year.
FY 2025 revenue guidance of $770 million to $800 million is reaffirmed.
Gozellix® launched in the U.S. and commercial dose deliveries commenced.
Gozellix has been assigned a Level II HCPCS code1 (effective 1 October 2025), a prerequisite for receiving Transitional Pass-Through payment status.
ProstACT™ Global Phase 3 trial milestone, all 30 patients consented for Part 1. Global expansion with regulatory approvals to expand the trial into China, Japan and Canada.
Q2 2025 Revenue (Unaudited)
Revenue$M
Q2 2025
Q2 2024
Variation
Q1 2025
Variation
Group revenue
204
125
63%
186
10%
Global Illuccix® revenue
154
123
25%
151
2%
RLS revenue1
46
-
-
332
39%
Commentary and business highlights
Dr. Christian Behrenbruch, Managing Director and Group CEO, Telix, stated, "Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., reinforcing the strength of our market position and continued customer demand. Despite emerging competitive pricing pressure, we have effective strategies in place to manage impact to average selling price. This includes the recent launch of Gozellix which has been assigned a HCPCS code, a crucial reimbursement milestone towards pass-through status. We continue to show positive momentum across multiple assets in our therapeutic pipeline, including achievement of a key recruitment milestone in our ProstACT Global Phase 3 trial."
Therapeutics business
TLX591 (177Lu-rosopatamab tetraxetan): Telix has consented all 30 patients required to complete Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Patients in two of the three arms (abiraterone and enzalutamide as standard of care) have completed dosing. An interim readout of safety and dosimetry will follow the completion of patient dosing, monitoring and data analysis. The trial is proceeding seamlessly into Part 2 at existing ex-U.S. sites and additional regulatory approvals have been obtained to commence the trial in China, Canada and Japan4.
TLX592 (225Ac-PSMA-RADmAb): Telix has submitted a Human Research Ethics Committee (HREC) application ...